Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

A. Nauck, Michael; J. Meier, Juris; A. Cavender, Matthew; Abd El Aziz, Mirna; J. Drucker, Daniel

doi:10.1161/circulationaha.117.028136

Public

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Published in Circulation • Aug 28, 2017

Authors:

Michael A. Nauck

Juris J. Meier

Matthew A. Cavender

Abstract

Potentiation of glucagon-like peptide-1 (GLP-1) action through selective GLP-1 receptor (GLP-1R) agonism or by prevention of enzymatic degradation by inhibition of dipeptidyl peptidase-4 (DPP-4) promotes glycemic reduction for the treatment of type 2 diabetes mellitus by glucose-dependent control of...

Subject

Medicine

Semaglutide

Lixisenatide

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!